0.0780
+0.0020
+(2.63%)
At close: 4:10:45 PM GMT+11
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Total Revenue
123,870.8680
123,870.8680
117,343.6330
66,991.7320
1,692.8400
Cost of Revenue
89,651.0790
89,651.0790
76,802.4190
41,564.5040
819.9120
Gross Profit
34,219.7890
34,219.7890
40,541.2140
25,427.2280
872.9280
Operating Expense
29,352.6620
29,352.6620
20,677.4300
16,188.4910
8,338.7950
Operating Income
4,867.1270
4,867.1270
19,863.7840
9,238.7370
-7,465.8670
Net Non Operating Interest Income Expense
-377.4590
-377.4590
108.8320
-432.3730
-247.5950
Other Income Expense
74.6000
74.6000
81.7110
254.9980
82.5380
Pretax Income
4,564.2680
4,564.2680
20,054.3270
9,744.6740
-4,205.8500
Tax Provision
1,314.0650
1,314.0650
6,304.0090
3,732.1650
--
Net Income Common Stockholders
3,512.3780
3,512.3780
13,809.3890
6,048.5340
-4,049.2090
Basic EPS
0.01
0.01
0.02
0.01
-0.03
Diluted EPS
0.01
0.01
0.02
0.01
-0.03
Basic Average Shares
569,927.3220
569,927.3220
555,198.6660
482,443.9390
128,750.0000
Diluted Average Shares
569,927.3220
569,927.3220
570,635.9090
487,785.0000
128,750.0000
Net Income from Continuing & Discontinued Operation
3,512.3780
3,512.3780
13,809.3890
6,048.5340
-4,049.2090
Normalized Income
3,512.3780
3,512.3780
13,809.3890
6,048.5340
-4,049.2090
Interest Income
669.8720
669.8720
334.3080
9.0670
46.5630
Interest Expense
1,047.3310
1,047.3310
225.4760
441.4400
294.1580
Net Interest Income
-377.4590
-377.4590
108.8320
-432.3730
-247.5950
EBIT
5,611.5990
5,611.5990
20,279.8030
10,186.1140
-3,911.6920
EBITDA
7,253.5310
7,253.5310
21,268.1590
10,869.4260
-486.6180
Reconciled Cost of Revenue
89,651.0790
89,651.0790
76,802.4190
41,564.5040
819.9120
Reconciled Depreciation
1,641.9320
1,641.9320
988.3560
683.3120
3,425.0740
Net Income from Continuing Operation Net Minority Interest
3,512.3780
3,512.3780
13,809.3890
6,048.5340
-4,049.2090
Normalized EBITDA
7,253.5310
7,253.5310
21,268.1590
10,869.4260
-486.6180
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0004
--
6/30/2021 - 11/6/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RGT.AX Argent BioPharma Limited
0.1400
-12.50%
VLS.AX Vita Life Sciences Limited
1.8800
+3.01%
PER.AX PERCHERON FPO [PER]
0.0080
0.00%
NXS.AX Next Science Limited
0.1300
+18.18%
MVP.AX Medical Developments International Limited
0.6650
+51.14%
SNT.AX Syntara Limited
0.0700
0.00%
HASH.V SIMPLY SOLVENTLESS CONCENTRATES
0.7700
+5.48%